The S&P/ASX 200 Index (ASX: XJO) has been volatile so far in 2026, and has shed over 6% since peaking at an all-time high in early March.
Many companies on the index are facing significant headwinds and issuing profit warnings or downgrading guidance. But there are a few ASX 200 shares going from strength to strength, and brokers tip they could fly up to 126% higher over the next 12 months.
Image source: Getty Images
Resolute Mining Ltd (ASX: RSG)
Resolute shares have enjoyed a fantastic rally over the past 12 months. At the time of writing, the shares are up 137% over the past year, and they're 13% higher for the year to date. As an ASX 200 gold stock, Resolute's shares have benefited from an uptick in gold over the past year. The miner has also reached some impressive feasibility milestones and posted a significant uptick in its gold production figures. The company expects production to keep climbing this year, too, to around 250,000 to 275,000 ounces at an all-in sustaining cost of $2,000 to $2,200. Brokers are very bullish on the shares and expect they could jump another 75% to $2.46 a piece, at the time of writing.
Life360 Inc (ASX: 360)
Life360 shares have faced a plethora of headwinds recently. From a tech-sector-wide sell-off, a rotation away from AI-related stocks, and concerns that prices had become overvalued. Slumping sentiment means the shares have now slumped 67% from an all-time high of $55.87 recorded in October last year. They're also down 43% for the year to date. But the ASX 200 company recently reported a 38% increase in revenue for the latest quarter, and upgraded its FY26 adjusted EBITDA and revenue guidance. Brokers are very bullish about the outlook for Life360 shares over the next 12 months, with consensus of a strong upside ahead. They tip the shares to climb another 83% to $34.01.
Cochlear Ltd (ASX: COH)
Cochlear shares crashed in April after the ASX healthcare company downgraded its FY26 earnings guidance, citing weaker conditions across developed markets and softer demand. At the time of writing, the shares are trading at the lowest level seen in over a decade. The guidance downgrade came off the back of a softer-than-expected half-year result earlier this year, and a sector-wide rotation away from ASX healthcare shares, as global volatility, a weaker US dollar, higher US tariffs, and increased labour costs prompted investors to sell up their holdings. Brokers aren't deterred, though. They still rate the stock as a buy and are tipping a potential 126% upside to $219.06, at the time of writing.
WiseTech Global Ltd (ASX: WTC)
WiseTech shares have been beaten down over the past 10 months, with the tech company hit by multiple and consecutive headwinds, including a tech-sector sell-off, AI concerns, and conflict in the Middle East, which sent its share price tumbling. The downturn has accelerated in 2026, and even after some promising upticks, the share price keeps on tumbling. At the time of writing, the shares have hit a four-year low. But the company maintains its FY26 guidance figures and expects a healthy EBITDA margin of around 40% to 41%. Brokers think the stock could stage a turnaround. They rate the ASX 200 share a strong buy and see 114% upside to $78.86 at the time of writing.
